Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) has been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $31.50.

Several research firms recently issued reports on VRDN. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, July 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Viridian Therapeutics in a report on Tuesday, June 11th. Wolfe Research began coverage on shares of Viridian Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $29.00 price target on the stock. LADENBURG THALM/SH SH cut shares of Viridian Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, May 9th. Finally, B. Riley downgraded Viridian Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the company from $25.00 to $20.00 in a report on Thursday, May 9th.

Institutional Trading of Viridian Therapeutics

Several hedge funds have recently bought and sold shares of VRDN. Ameritas Investment Partners Inc. grew its position in Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after purchasing an additional 799 shares during the last quarter. Quest Partners LLC grew its position in Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after purchasing an additional 4,692 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Viridian Therapeutics by 122.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock worth $182,000 after purchasing an additional 4,610 shares during the last quarter. Arizona State Retirement System bought a new position in Viridian Therapeutics in the 4th quarter worth about $208,000. Finally, Principal Financial Group Inc. grew its position in Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after purchasing an additional 1,058 shares during the last quarter.

Viridian Therapeutics Stock Down 0.7 %

Shares of Viridian Therapeutics stock opened at $15.02 on Wednesday. Viridian Therapeutics has a 1-year low of $10.93 and a 1-year high of $24.18. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.99 and a quick ratio of 23.99. The company has a market capitalization of $958.58 million, a PE ratio of -3.34 and a beta of 1.13. The business has a 50-day moving average of $13.76 and a 200-day moving average of $15.55.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.